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Introduction
Metabolic acidosis is a common biochemical disturbance. It can result from an inability of the kidneys to excrete a hydrogen ion load, loss of bicarbonate from the renal or gastrointestinal tracts or increased generation of hydrogen ions. Calculation of the anion gap, ([Na þ ] þ [K þ ])À([Cl À ] þ [HCO 3 À ]), may be useful in elucidating the cause of a metabolic acidosis. In acidosis due to renal tubular acidosis or loss of bicarbonate the anion gap is normal. Usual causes of a high anion gap metabolic acidosis include raised lactate and ketones, ingestion of toxic substances such as methanol and ethylene glycol, and chronic renal failure. We present two adult patients with a high anion gap metabolic acidosis secondary to acquired pyroglutamic aciduria (5-oxoprolinuria).
Case 1
An 82-year-old woman was admitted to the orthopaedic ward with an infected total hip prosthesis. This was surgically washed out and she was commenced on intravenous £ucloxacillin and prescribed paracetamol 1g four times daily as analgesia. Three weeks later she underwent the ¢rst stage of a revision procedure. Cultures revealed growth of Staphylococcus aureus and Pseudomonas and rifampicin and levo£oxacin were added to her treatment regimen. After a further four weeks she became acutely unwell with nausea, confusion and ataxia. Her level of consciousness was decreased (Glasgow Coma Score of 9/15) but she had no focal neurological signs. The results of her investigations are shown in Table 1 . Her other liver function test (LFT) results were normal. Dipstick urinalysis was positive for ketones.
A computed tomography (CT) scan of her head was unremarkable but an electroencephalogram (EEG) showed features of metabolic encephalopathy. Organic acid analysis of her urine using gas chromatography mass spectrometry (GC-MS) showed pyroglutamic aciduria ( Figure 1a ). She was treated conservatively with £uid and electrolyte replacement and her antibiotics and paracetamol were discontinued. She made an uneventful recovery and was transferred back to the orthopaedic ward after 4 days. Repeat urinary organic acid analysis two weeks later showed normal levels of pyroglutamate ( Figure 1b ).
Case 2
A 53-year-old man was admitted under the care of the surgical team with sepsis secondary to a pelvic collection. He had a past history of rheumatoid arthritis and ulcerative colitis and had undergone colectomy and ileostomy three months previously. His medications on admission included paracetamol and diclofenac for analgesia and omeprazole and metoclopramide. The abscess was drained and he was commenced on antibiotics, initially augmentin, gentamicin, later metronidazole and levo£oxacin in addition to vancomycin. He was initially fed enterally but after three weeks, due to concerns over the possible development of a ¢stula, he was commenced on total parenteral nutrition (TPN).
One week later he deteriorated, becoming disorientated. A CT of his head was normal. The results of his investigations are also shown in Table 1 . His other LFT results were normal. Examination of his urine revealed the presence of pyroglutamic acid. Antibiotics and paracetamol were discontinued but he deteriorated and died, secondary to a myocardial infarction.
Discussion
Pyroglutamic aciduria is a biochemical disturbance resulting from increased production and urinary excretion of pyroglutamic acid (5-oxoproline) and has been described in both paediatric and adult patients. Increased pyroglutamic acid excretion is an indication that there is an abnormality in the metabolic pathway involved in synthesis of the intracellular reducing agent glutathione and the response to oxidative stress. Inherited defects have been described in the enzymes in the g-glutamyl cycle, those in glutathione synthetase and 5-oxoprolinase having a marked e¡ect on pyroglutamic acid excretion ( Figure 2 ). 1 Glutathione synthetase de¢ciency leads to a reduction in glutathione and loss of feedback inhibition on g-glutamylcysteine synthetase. These factors contribute to accumulation of g-glutamylcysteine, which is in turn converted to pyroglutamic acid. Clinically the increased pyroglutamic acid causes a severe metabolic acidosis and the glutathione de¢ciency is associated with haemolytic anaemia and neurological dysfunction.5-Oxoprolinase de¢ciency whilst associated with pyroglutamic aciduria does not result in severe metabolic acidosis and glutathione production is not a¡ected.
Transient pyroglutamic aciduria has also been described in adults. 2--6 As in our patients the history is classically of a single acute episode but recurrent episodes of pyroglutamic aciduria have also been described. 7 Both of our patients are also typical in having been prescribed paracetamol and antibiotics which are known to be risk factors, 3, 5, 6 but unusual in that both had normal creatinine concentrations. The presence of betahydroxybutyrate and acetoacetate in the urine of our ¢rst patient might have suggested a possible explanation for her high anion gap, but further investigations showed the presence of pyroglutamic acid. Our second case is particularly interesting as he is male (the majority of patients reported in the literature being females), and this may represent genderrelated di¡erences in the metabolism of paracetamol or glutathione. 3 The majority of ingested paracetamol is conjugated to glucuronide and sulphate and excreted renally. When supplies of glucuronide and sulphate are exhausted, more paracetamol is available to the P450 cytochrome enzymes in the liver, which convert it into the toxic metabolite N-acetyl p-benzoquinoneimine (NAPQI). This metabolite is conjugated to glutathione and excreted renally. Chronic ingestion of paracetamol may lead to glutathione depletion and accumulation of g-glutamylcysteine resulting in pyroglutamic aciduria (Figure 2) . Administration of N-acetyl cysteine could be bene¢cial by increasing glutathione levels. 3, 6 Antibiotics, notably £ucloxacillin, have been postulated to be associated with inhibition of 5-oxoprolinase which would hinder the metabolism of pyroglutamic acid. 5 Complete recovery from this acidosis has commonly been shown to be related to discontinuation of the paracetamol 3,6 and antibiotics. 5 It is unlikely that drug ingestion alone accounts for the severity of the pyroglutamic aciduria in these patients. Glutathione is a tripeptide synthesised from glutamate, cysteine and glycine. Our second patient was receiving TPN at the time of presentation with pyroglutamic aciduria. It has been shown that pyroglutamic acid excretion increases in states where demands for glycine are high such as pregnancy 8 or sepsis, and nutritional glycine de¢ciency may have been involved in the aetiology of the pyroglutamic aciduria. Unlike glycine, glutamate is not included in standard TPN feed, but both are considered to be conditionally essential amino acids with increased requirements under conditions of stress. Supplementation of TPN feed with glutathione has been shown to increase plasma levels. 9 The ketonuria, hypokalaemia, hypomagnesaemia and hypophosphataemia in our ¢rst patient may also be indicative of a poor nutritional status.
Early reports of increased pyroglutamic levels in patients on arti¢cial diets derived from hydrolysed casein were dietary in origin as a result of the presence pyroglutamic acid in the dietary supplements. 10 Pyroglutamic acid is no longer a component of TPN feed, although it can be purchased from health food shops and over the internet as a supplement promoted to improve cognitive function. It is closely related in structure to nootropic drugs such as piracetam and oxiracetam. 11 Our ¢rst case is typical of that of an adult patient presenting with pyroglutamic aciduria, being female with a history of therapeutic paracetamol and antibiotic use. Our second patient had additional risk factors associated with the use of parenteral nutrition. These cases both presented to us within ¢fteen months of each other leading us to suspect that the condition may be relatively common but go undetected in hospital patients with high anion gap metabolic acidosis. We wish to raise awareness of it and propose parenteral nutrition or nutritional compromise as an additional risk factor for its development.
